USA — Medical technology giant BD and Company has unveiled its latest innovation, the PIVO Pro Needle-free Blood Collection Device, following 510(k) clearance from the U.S. Food and Drug Administration (FDA).
This new device is designed to work seamlessly with integrated and long peripheral IV catheters, expanding its compatibility beyond traditional short peripheral IV catheters.
The PIVO Pro device is a significant step forward in BD’s pursuit of a “One-Stick Hospital Stay,” as it merges the benefits of the integrated Nexiva Catheter System with the capability to draw high-quality blood samples directly from a patient’s peripheral IV line.
This not only reduces the need for additional needlesticks but also enhances the patient experience by addressing needle phobia, a concern that affects more than 60% of the adult population.
BD recognizes that peripheral IV insertion and blood collection are among the most common in-patient procedures in hospitals, touching nearly every patient daily.
However, these procedures often lead to complications such as poor first-stick insertion success, catheter failures, and low-quality samples. This can result in extended hospital stays, increased costs, and patient dissatisfaction.
The PIVO Pro, when used with the Nexiva with NearPort IV Access, is engineered to create optimal conditions for blood draws. This not only enhances clinician efficiency but also improves the overall patient experience.
The innovative solution has demonstrated the ability to optimize IV performance, reduce sample errors that necessitate redraws, and prevent complications that lead to unnecessary procedures and IV replacements.
By eliminating the need for needles during blood draws and reducing IV replacements, it can also minimize the risk of needlestick injuries and blood exposure for healthcare professionals, all while preserving the patient’s vessel health.
The PIVO technology, first introduced in 2017, has been instrumental in minimizing the number of needlesticks for patients by enabling high-quality blood sample collection through an existing peripheral IV catheter line, using a single access point.
According to the company, over 3.5 million PIVO procedures have been conducted in the U.S. to date, symbolizing the elimination of one or more needlesticks for each patient.
This innovation represents a significant advancement in healthcare technology that aims to improve patient care and reduce the anxiety associated with needle-based procedures.
BD sells surgical instrumentation platform to Steris in US$540 million deal
Becton, Dickinson and Company (BD) entered into a definitive agreement to divest its surgical instrumentation platform to Steris for US$540 million.
This deal encompasses a range of products, including V. Mueller and Snowden-Pencer laparoscopic instruments, and Genesis sterilization containers.
Moreover, it includes three manufacturing facilities strategically located in St. Louis, MO, Cleveland, OH, and Tuttlingen, Germany.
As part of this transition, approximately 360 employees responsible for supporting the platform will join the Steris team upon the transaction’s successful completion.
BD’s decision to divest its surgical instrumentation platform is closely aligned with the “simplify” pillar of the company’s 2025 strategy, which aims to streamline BD’s product portfolio and manufacturing network.
This strategic move supports revenue growth and market expansion, reflecting the company’s efforts to adapt to the evolving landscape of the healthcare industry.
BD is not alone in implementing such strategies, as several companies are making similar adjustments due to uncertain economic conditions and changing dynamics in the healthcare sector.
This strategic decision follows in the footsteps of other industry leaders like Siemens Healthineers, who recently announced a comprehensive overhaul of its diagnostics division.
Siemens Healthineers has laid off 67 employees from its manufacturing facility in Flanders, New Jersey, as part of the consolidation of its Atellica Solution IM module manufacturing to its Swords site in Dublin, Ireland.
This move comes as a response to a 39% downturn in 2Q23 revenue, driven by decreased demand for rapid COVID-19 antigen tests.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
